Gentamicin/vancomycin - Dr Reddys Laboratories
Alternative Names: DFA-02; Vancomycin/gentamicin; XimycinLatest Information Update: 10 Oct 2018
At a glance
- Originator Dr Reddys Laboratories; Duke Clinical Research Institute
- Class Aminoglycosides; Antibacterials; Glycopeptides; Peptide antibiotics; Small molecules
- Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Surgical wound infections
Most Recent Events
- 01 Oct 2018 Dr. Reddy’s Laboratories regains worldwide rights of gentamicin/vancomycin gel from Armis Biopharma for Surgical wound infections
- 07 Feb 2018 Armis Biopharma has patent protection for gentamicin/vancomycin
- 29 Jan 2018 Armis Biopharma plans a phase III registration trial for Surgical wound infections (Surgical site infections) (Prevention) in first half of 2018